Search Result

Results for "

Trk inhibitors

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Trk Receptor (82) Akt (1) Anaplastic lymphoma kinase (ALK) (3) Apoptosis (12) Autophagy (4) Bcr-Abl (1) c-Fms (1) c-Kit (1) c-Met/HGFR (3) CaMK (1) CDK (2) CXCR (1) Discoidin Domain Receptor (1) Drug Metabolite (1) E3 Ligase Ligand-Linker Conjugates (1) EGFR (1) ERK (2) FLT3 (3) IFNAR (1) Interleukin Related (1) Isotope-Labeled Compounds (1) Itk (1) Ligands for Target Protein for PROTAC (1) PDGFR (1) PKA (1) PKC (1) Prostaglandin Receptor (1) PROTACs (3) Reactive Oxygen Species (ROS) (2) Reference Standards (8) RET (1) ROS Kinase (4) VEGFR (2) Wnt (2)
By Research Areas:	Cancer (78) Cardiovascular Disease (1) Endocrinology (1) Infection (2) Inflammation/Immunology (5) Neurological Disease (10)

By Targets:

Trk Receptor (82)

Akt (1)

Anaplastic lymphoma kinase (ALK) (3)

Apoptosis (12)

Autophagy (4)

Bcr-Abl (1)

c-Fms (1)

c-Kit (1)

c-Met/HGFR (3)

CaMK (1)

CDK (2)

CXCR (1)

Discoidin Domain Receptor (1)

Drug Metabolite (1)

E3 Ligase Ligand-Linker Conjugates (1)

EGFR (1)

ERK (2)

FLT3 (3)

IFNAR (1)

Interleukin Related (1)

Isotope-Labeled Compounds (1)

Itk (1)

Ligands for Target Protein for PROTAC (1)

PDGFR (1)

PKA (1)

PKC (1)

Prostaglandin Receptor (1)

PROTACs (3)

Reactive Oxygen Species (ROS) (2)

Reference Standards (8)

RET (1)

ROS Kinase (4)

VEGFR (2)

Wnt (2)

By Research Areas:

Cancer (78)

Cardiovascular Disease (1)

Endocrinology (1)

Infection (2)

Inflammation/Immunology (5)

Neurological Disease (10)

Inhibitors & Agonists

Natural
Products

Isotope-Labeled Compounds

Targets Recommended: Trk Receptor Serpin

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-N0020

Echinacoside 15+ Cited Publications	Wnt Reactive Oxygen Species (ROS)	Neurological Disease
Echinacoside, one of the phenylethanoids isolated from the stems of Cistanche deserticola, effectively inhibits Wnt/β-catenin signaling. Echinacoside elicits neuroprotection by activating Trk receptors and their downstream signal pathways. Antiosteoporotic activity .

HY-12866

Larotrectinib 15+ Cited Publications LOXO-101; ARRY-470	Trk Receptor Apoptosis	Cancer
Larotrectinib (LOXO-101) is an ATP-competitive oral, selective inhibitor of the tropomyosin-related kinase *(TRK)* family receptors, with low nanomolar 50% inhibitory concentrations against all three isoforms (TRKA, B, and C).

HY-103022

Repotrectinib 5+ Cited Publications TPX-0005	ROS Kinase Trk Receptor Anaplastic lymphoma kinase (ALK)	Cancer
Repotrectinib (TPX-0005) is a potent ROS1 (IC₅₀=0.07 nM) and *TRK* (IC₅₀=0.83/0.05/0.1 nM for TRKA/B/C) inhibitor. Repotrectinib potently inhibits WT ALK (IC₅₀=1.01 nM). Repotrectinib has anti-cancer activity .

HY-N6732

K-252a 25+ Cited Publications SF2370; Antibiotic K 252a; Antibiotic SF 2370	Autophagy PKA PKC Trk Receptor CaMK	Infection Inflammation/Immunology
K-252a, a staurosporine analog, inhibits protein kinase, with IC₅₀ values of 470 nM, 140 nM, 270 nM, and 1.7 nM for PKC, PKA, Ca ²⁺/calmodulin-dependent kinase type II, and phosphorylase kinase, respectively . K-252a is a potent inhibitor (IC₅₀ of 3 nM) of the tyrosine protein kinase (TRK) activity of the NGF receptor gp140trk, the product of the trk protooncogene .

HY-13491

GNF-5837 4 Publications Verification	Trk Receptor	Cancer
GNF-5837 is a potent, selective, and orally bioavailable pan-tropomyosin receptor kinase (TRK) inhibitor which display antiproliferative effects in cellular Ba/F3 assays ( IC₅₀ values of 7 nM, 9 nM and 11 nM for cells containing the fusion proteins Tel-TrkC, Tel-TrkB and Tel-TrkA, respectively) .

HY-101977

Selitrectinib 5 Publications Verification LOXO-195	Trk Receptor	Cancer
Selitrectinib (LOXO-195) is a next-generation TRK kinase inhibitor, with IC₅₀s of 0.6 nM and <2.5 nM for TRKA and TRKC, respectively .

HY-152292

Zidesamtinib NVL-520; NUV-520	ROS Kinase	Cancer
Zidesamtinib (NVL-520) is a potent, selective, orally active and brain-penetrant inhibitor of diverse ROS1 fusions and resistance mutations, with IC₅₀s of 0.7 and 7.9 nM for wild-type ROS1 and ROS1 G2032R, respectively, and spares TRK inhibition. Zidesamtinib can be used for the research of cancer .

HY-10424

Milciclib 5+ Cited Publications PHA-848125	CDK Autophagy	Cancer
Milciclib (PHA-848125) is a potent, ATP-competitive and dual inhibitor of CDK and Tropomyosin receptor kinase (TRK), with IC₅₀s of 45, 150, 160, 363, 398 nM and 53 nM for cyclin A/CDK2, cyclin H/CDK7, cyclin D1/CDK4, cyclin E/CDK2, cyclin B/CDK1 and TRKA, respectively.

HY-148811

Zurletrectinib ICP-723	c-Met/HGFR Trk Receptor	Cancer
Zurletrectinib is a brain-penetrant, orally active *TRK* inhibitor (TRKA IC₅₀ = 0.81 nM; TRKB IC₅₀ = 0.145 nM; TRKC IC₅₀ = 0.184 nM). Zurletrectinib exhibits stronger activity as a consequence of its augmented binding affinity for TRK kinases. Zurletrectinib exhibits higher activity against most TRK inhibitor resistance mutations (13 out of 18 mutations). Zurletrectinib can be used for the study of glioma .

HY-12866A

Larotrectinib sulfate 15+ Cited Publications LOXO-101 sulfate; ARRY-470 sulfate	Trk Receptor Apoptosis	Cancer
Larotrectinib sulfate (LOXO-101 sulfate; ARRY-470 sulfate) is an ATP-competitive oral, selective inhibitor of the tropomyosin-related kinase *(TRK)* family receptors, with low nanomolar 50% inhibitory concentrations against all three isoforms (TRKA, B, and C).

HY-B0791

Altiratinib 1 Publications Verification DCC-2701	VEGFR c-Met/HGFR FLT3 Trk Receptor	Cancer
Altiratinib (DCC-2701) is a multi-targeted kinase inhibitor with IC₅₀s of 2.7, 8, 9.2, 9.3, 0.85, 4.6, 0.83 nM for MET, TIE2, VEGFR2, FLT3, *Trk1, Trk2, and Trk3* respectively.

HY-15590

AZ-23 3 Publications Verification AZD1332	Trk Receptor	Cancer
AZ-23 is an ATP-competitive and orally bioavailable Trk kinase A/B/C inhibitor with IC₅₀s of 2 nM (TrkA), 8 nM (TrkB), 24 nM (FGFR1), 52 nM (Flt3), 55 nM (Ret), 84 nM (MuSk), 99 nM (Lck), respectively.

HY-137465

CG428	PROTACs Trk Receptor	Cancer
CG428 is a potent and selective CRBN-dependent tropomyosin receptor kinase (TRK) PROTAC degrader that has anti-tumor activity. CG428 reduces levels of the tropomyosin 3 TPM3-TRKA fusion protein in KM12 colorectal carcinoma cells (DC₅₀ = 0.36 nM) and inhibits downstream PLCγ1 phosphorylation (IC₅₀ = 0.33 nM). CG428 has a higher binding affinity for TRKA than TRKB and TRKC (Kd = 1 nM, 28 nM and 4.2 nM, respectively). CG428 can be used for the research of colorectal carcinoma .

HY-122616

PF-06273340	Trk Receptor	Neurological Disease
PF-06273340 is a peripherally restricted pan-Trk inhibitor with IC₅₀ values of 6, 4, 3 nM for TrkA, TrkB, and TrkC receptors. PF-06273340 binds in a DFG-out conformation, targeting less conserved kinase ligand binding domain regions outside the ATP binding pocket. PF-06273340 exhibits anti-hyperalgesic and analgesic effects. PF-06273340 can be used for the research of pain .

HY-46531

Thalidomide-5-NH2-CH2-COOH	E3 Ligase Ligand-Linker Conjugates Autophagy Apoptosis	Inflammation/Immunology Cancer
Thalidomide-5-NH2-CH2-COOH (compound 114) is a potent and selective inhibitor of tropomyosin receptor kinase (trk). Thalidomide-5-NH2-CH2-COOH is a ligand of E3 ligase. Thalidomide-5-NH2-CH2-COOH has the potential for researching one or more diseases (extracted from patent WO2021170109A1) .

HY-102066

Utatrectinib AZD-7451	Trk Receptor	Cancer
Utatrectinib (AZD-7451) is a potent, selective and orally active *Trk* inhibitor. Utatrectinib blocks TrkC activation and associated tumorigenic behaviors .

HY-131706A

GNF-8625 monopyridin-N-piperazine hydrochloride 1 Publications Verification	Trk Receptor	Cancer
GNF-8625 monopyridin-N-piperazine hydrochloride (TRKi-2), a TRK inhibitor, which is from the patent WO 2020038415 A1 .

HY-107362

CH7057288	Trk Receptor	Cancer
CH7057288 is a potent and selective *TRK* inhibitor. CH7057288 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-100695

DDR-TRK-1	Discoidin Domain Receptor	Cancer
DDR-TRK-1, a chemical probe, is a selective Discoidin Domain Receptor 1 (DDR1) inhibitor, with an IC₅₀ value of 9.4 nM. DDR-TRK-1 also inhibits TRK family.

HY-112436

PF-6683324 Trk-IN-4	Trk Receptor	Neurological Disease
PF-6683324 (Trk-IN-4) is a potent *pan-Trk* inhibitor in cell-based assays with IC₅₀s of 1.9 nM, 2.6 nM and 1.1 nM for TrkA, TrkB and TrkC, respectively . Anti-hyperalgesic effect .

HY-157542

CG428-NEG	Trk Receptor PROTACs	Others
CG428-NEG is a TRK degrader negative control. CG428 (HY-137465) inhibits cell growth and reduce TPM3-TRKA levels .

HY-112437

PF-06737007	Trk Receptor	Neurological Disease
PF-06737007 is a potent *pan-Trk* inhibitor in cell-based assays with IC₅₀s of 7.7 nM, 15 nM and 3.9 nM for TrkA, TrkB and TrkC, respectively . Anti-hyperalgesic effect .

HY-N0020R

Echinacoside (Standard)	Reference Standards Wnt Reactive Oxygen Species (ROS)	Neurological Disease
Echinacoside (Standard) is the analytical standard of Echinacoside. This product is intended for research and analytical applications. Echinacoside, one of the phenylethanoids isolated from the stems of Cistanche deserticola, effectively inhibits Wnt/β-catenin signaling. Echinacoside elicits neuroprotection by activating Trk receptors and their downstream signal pathways. Antiosteoporotic activity .

HY-19295

TRK-530 sodium	CXCR	Inflammation/Immunology Endocrinology
TRK-530 sodium is an orally active bisphosphonate. TRK-530 sodium inhibits CINC-1. TRK-530 sodium inhibits dental calculus formation. TRK-530 sodium also inhibits paw edema, joint destruction and osteomyelitis .

HY-144321

Trk-IN-9	Trk Receptor	Cancer
Trk-IN-9 (Compound 12) is a potent inhibitor of *TRK. Trk-IN-9 inhibits* the proliferation of Km-12 cell lines. Trk-IN-9 induces the apoptosis of Km-12 cells in a concentration-dependent manner. Trk-IN-9 inhibits the phosphorylation of TRK to block downstream pathways. Trk-IN-9 has the potential for the research of NTRK-fusion cancers .

HY-146697

IHMT-TRK-284	Trk Receptor c-Fms PDGFR Bcr-Abl c-Kit Apoptosis	Cancer
IHMT-TRK-284 (Compound 34) is a potent, orally active *type II TRK* kinase** inhibitor with IC₅₀ values of 10.5, 0.7, and 2.6 nM to TRKA, B, and C respectively. IHMT-TRK-284 displays great selectivity profile in the kinome and good in vivo antitumor efficacies .

HY-175271

JWJ-01-378	PROTACs Trk Receptor ERK	Cancer
JWJ-01-378 is a selective *TRK* PROTAC degrader. JWJ-01-378 efficiently degrades WT TRK and TPM3-TRKA fusion proteins and inhibits downstream pERK signaling, while showing limited efficacy against TRK inhibitor resistant mutants and ALK fusions. JWJ-01-378 potently suppresses cancer cell proliferation .Pink: TRK ligand (HY-160520); Blue: CRBN ligase ligand (HY-103596); Black: linker

HY-177082

Eratrectinib	Trk Receptor	Cancer
Eratrectinib (Example 1) is a *Trk* inhibitor. Eratrectinib can be studied in research for tropomyosin receptor kinase-related diseases and cancers .

HY-124637

ALE-0540	Trk Receptor	Neurological Disease
ALE-0540, a nonpeptidic small molecule, is a nerve growth factor receptor antagonist. ALE-0540 inhibits the binding of NGF to tyrosine kinase (Trk) A or both p75 and TrkA with IC₅₀ values of 5.88 μM and 3.72 μM, respectively. ALE-0540 can be used to examine mechanisms leading to the development of agents for the study of pain .

HY-174161

*Type II TRK inhibitor* 3**	Trk Receptor	Cancer
Type II TRK inhibitor 3 (Compound 18d) is a Type II TRK inhibitor with IC50 values of 0.82, 1.82, and 0.12 nM for TRKAWT/G595R/G667C, respectively. Type II TRK inhibitor 3 exhibits antitumor activity .

HY-120393

GZ-389988	Trk Receptor	Cancer
GZ-389988 is a potent pan-TRK inhibitor with IC₅₀ values of 0.3, 0.1, and 0.5 nM for TRKA, TRKB, and TRKC, respectively. GZ-389988 can be used to study NTRK fusion-positive tumors .

HY-161179

TRK-IN-27	Trk Receptor	Cancer
TRK-IN-27 (Compound 14q) is a potent *TRK* inhibitor with good kinase selectivity. TRK-IN-27 effectively inhibits tumor growth .

HY-150258

TRK-IN-22	Trk Receptor	Others
TRK-IN-22 (compound 11) is a *TRK* inhibitor. TRK-IN-22 (compound 11), a typical type I inhibitor, covers the ATP-binding pocket of TRKA .

HY-175302

TRK-IN-32	Trk Receptor Apoptosis	Cancer
TRK-IN-32 is a potent *TRK* inhibitor. TRK-IN-32 potently inhibits TRK ^WT, TRK ^G595R and TRK ^G667C with IC₅₀ values of 0.08 nM, 2.14 nM and 0.68 nM, respectively. TRK-IN-32 also demonstrates antiproliferative activity against a panel of Ba/F3 cell lines transformed with wild type, xDFG, solvent-front as well as gatekeeper mutant TRK fusion proteins. TRK-IN-32 induces apoptosis of Ba/F3-TRKA ^WT and Ba/F3-TRKA ^G667C cells.TRK-IN-32 can be used for the study of various cancers (such as thyroid cancer, secretory breast carcinoma) .

HY-160165

TRK-IN-25	Trk Receptor	Cancer
TRK-IN-25 (compound 16) is a *Trk* inhibitor with antiproliferative activity against cancer cells. TRK-IN-25 can be used in cancer research .

HY-160166

TRK-IN-26	Trk Receptor	Cancer
TRK-IN-26 (compound 12) is a *TRK* inhibitor with potential for cancer research .

HY-174330A

TRK-IN-31 hydrochloride	Trk Receptor	Cancer
TRK-IN-31 hydrochloride is an orally active *TRK* inhibitor with an IC₅₀ of 1.8 nM. TRK-IN-31 hydrochloride has superior antiproliferative activity in the Ba/F3-MPRIP-TRKA ^G667C cells, and potently inhibits TRK kinase activity with high selectivity. TRK-IN-31 hydrochloride significantly inhibits tumor growth in Ba/F3-MPRIP-TRKA ^G667C subcutaneous tumor mice model .

HY-174330

TRK-IN-31	Trk Receptor	Cancer
TRK-IN-31 is an orally active *TRK* inhibitor with an IC₅₀ of 1.8 nM. TRK-IN-31 has superior antiproliferative activity in the Ba/F3-MPRIP-TRKA ^G667C cells, and potently inhibits TRK kinase activity with high selectivity. TRK-IN-31 significantly inhibits tumor growth in Ba/F3-MPRIP-TRKA ^G667C subcutaneous tumor mice model .

HY-161819

TRK-IN-29	Trk Receptor	Cancer
TRK-IN-29 (Compound B31) is a second-generation *TRK* inhibitor (IC₅₀: 9 nM, 0.6 nM, 18 nM, 5 nM, 6 nM for TRKA ^G595R, TRKA ^F589L, TRKA ^G667C, TRKA and TRKC respectively). TRK-IN-29 inhibits the phosphorylation of TRKA. TRK-IN-29 has good antiproliferative activities against NTRK fusion positive cells. TRK-IN-29 has exellent plasma stability and moderate pharmacokinetic properties .

HY-151945

TRK II-IN-1	Trk Receptor FLT3 VEGFR RET	Cancer
TRK II-IN-1 is a potent type II *TRK* inhibitor, with IC₅₀s of 3.3, 6.4, 4.3 and 9.4 nM, for TRKA/B/C and TRKA ^G667C, respectively. TRK II-IN-1 also inhibits FLT3, RET, and VEGFR2 with IC₅₀s of 1.3, 9.9, and 71.1 nM, respectively. TRK II-IN-1 can be used for the research of TRK driven cancers .

HY-144423

Trk-IN-10	Trk Receptor	Cancer
Trk-IN-10 (Compound 14j) is a potent inhibitor of *TRK* (IC₅₀ = 0.86, 6.92 nM, against TrkA, TrkA ^G595R, respectively). As a receptor tyrosine kinase (RTK), tropomyosin receptor kinase (Trk) is a key agent target in solid tumors. Trk-IN-10 (IC₅₀ = 350 nM against ALK) has a higher selectivity of Trk inhibition, which may be of great significance for reducing toxicity .

HY-146115

TRK-IN-19	Trk Receptor	Cancer
TRK-IN-19 (Compound I-10 ) is a potent inhibitor of *TRK* (TRKA IC₅₀ = 1.1 nM, TRKA ^G595R IC₅₀ = 5.3 nM). TRK-IN-19 has the potential for the research of cancer diseases .

HY-146521

TRK-IN-15	Trk Receptor	Cancer
TRK-IN-15 is a potent inhibitor of *TRK. Protein kinases play a critical role in the control of cell growth and differentiation and are responsible for the control of a wide variety of cellular signal transduction processes. TRK-IN-15 has the potential for the research of TRK*-related diseases (extracted from patent WO2012034091A1, compound X-55) .

HY-146522

TRK-IN-16	Trk Receptor	Cancer
TRK-IN-16 is a potent inhibitor of *TRK. Protein kinases play a critical role in the control of cell growth and differentiation and are responsible for the control of a wide variety of cellular signal transduction processes. TRK-IN-16 has the potential for the research of TRK*-related diseases (extracted from patent WO2012034091A1, compound X-21) .

HY-146519

TRK-IN-14	Trk Receptor	Cancer
TRK-IN-14 is a potent inhibitor of *TRK. Protein kinases play a critical role in the control of cell growth and differentiation and are responsible for the control of a wide variety of cellular signal transduction processes. TRK-IN-14 has the potential for the research of TRK*-related diseases (extracted from patent WO2012034091A1, compound X-47) .

HY-144424

Trk-IN-11	Trk Receptor	Cancer
Trk-IN-11 (Compound 14h) is a potent inhibitor of *TRK* (IC₅₀ = 1.4, 1.8 nM, against TrkA, TrkA ^G595R, respectively). As a receptor tyrosine kinase (RTK), tropomyosin receptor kinase (Trk) is a key agent target in solid tumors. Trk-IN-11 has the potential for the research of cancer disease .

HY-146518

TRK-IN-13	Trk Receptor	Cancer
TRK-IN-13 is a potent inhibitor of *TRK. Protein kinases play a critical role in the control of cell growth and differentiation and are responsible for the control of a wide variety of cellular signal transduction processes. TRK-IN-13 has the potential for the research of TRK*-related diseases (extracted from patent WO2012034091A1, compound X-24) .

HY-146807

*Type II TRK inhibitor* 1**	Trk Receptor	Cancer
Type II TRK inhibitor 1 is a potent *TRK* inhibitor, which inhibits various TRK fusion protein variants and wild type. Type II TRK inhibitor 1 exhibits antiproliferative activity against Ba/F3 cells harboring CD74-TRKA ^G667C and ETV6-TRKC ^G696C fusion proteins with IC₅₀s of 6 nM and 1.7 nM, respectively . Type II TRK inhibitor 1 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-163004

*Type II TRK inhibitor* 2**	Trk Receptor	Cancer
Type II TRK inhibitor 2 (compound 40l) is a selective type II *TRK* inhibitor with plasma stability and moderate hepatic microsomal stability. Type II TRK inhibitor 2 significantly inhibits Km-12, Ba/F3-TRKA ^G595R and Ba/F3-TRKA ^G667C cell proliferation (IC₅₀: 4.1 nM, 41.5 nM, 1.4 nM). Type II TRK inhibitor 2 can be used to study NTRK fusion cancers .

HY-144732

TRK/ALK-IN-1	Trk Receptor Anaplastic lymphoma kinase (ALK)	Cancer
TRK/ALK-IN-1 (compound 21) is a potent and dual inhibitor of *TRK* and ALK. TRK/ALK-IN-1 in the enzymatic assays is in good accordance with anti-proliferative activity with IC₅₀ values of 2.2, 9.3 and 38 nM towards TRKA, ALK ^WT and ALK ^L1196M, respectively. TRK/ALK-IN-1 has the potential for the research of cancer diseases .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N0020

Echinacoside 15+ Cited Publications	Structural Classification Simple Phenylpropanols Cistanche deserticola Ma Phenols Polyphenols Orobanchaceae Phenylpropanoids Plants Source Classification	Wnt Reactive Oxygen Species (ROS)
Echinacoside, one of the phenylethanoids isolated from the stems of Cistanche deserticola, effectively inhibits Wnt/β-catenin signaling. Echinacoside elicits neuroprotection by activating Trk receptors and their downstream signal pathways. Antiosteoporotic activity .

HY-N6732

K-252a 25+ Cited Publications SF2370; Antibiotic K 252a; Antibiotic SF 2370	Alkaloids Structural Classification Microorganisms Classification of Application Fields Inflammation/Immunology Disease Research Fields Indole Alkaloids Source Classification	Autophagy PKA PKC Trk Receptor CaMK
K-252a, a staurosporine analog, inhibits protein kinase, with IC₅₀ values of 470 nM, 140 nM, 270 nM, and 1.7 nM for PKC, PKA, Ca ²⁺/calmodulin-dependent kinase type II, and phosphorylase kinase, respectively . K-252a is a potent inhibitor (IC₅₀ of 3 nM) of the tyrosine protein kinase (TRK) activity of the NGF receptor gp140trk, the product of the trk protooncogene .

HY-N0020R

Echinacoside (Standard)	Structural Classification Simple Phenylpropanols Cistanche deserticola Ma Phenols Polyphenols Orobanchaceae Phenylpropanoids Plants Source Classification	Reference Standards Wnt Reactive Oxygen Species (ROS)
Echinacoside (Standard) is the analytical standard of Echinacoside. This product is intended for research and analytical applications. Echinacoside, one of the phenylethanoids isolated from the stems of Cistanche deserticola, effectively inhibits Wnt/β-catenin signaling. Echinacoside elicits neuroprotection by activating Trk receptors and their downstream signal pathways. Antiosteoporotic activity .

Cat. No.	Product Name	Chemical Structure

HY-166363S

Beraprost-d3

Beraprost-d₃ (TRK-100-d₃) is deuterium labeled (Rac)-Beraprost. (Rac)-Beraprost ((Rac)-ML 1229) is an orally active prostacyclin analog that inhibits the release of Ca ²⁺ from intracellular storage sites by binding to prostacyclin membrane receptors (Prostaglandin Receptor), leading to relaxation of smooth muscle cells and vasodilation. Beraprost has vasodilatory, antiplatelet, and cytoprotective effects, making it promising for research in the field of cardiovascular diseases, such as thromboangiitis obliterans and atherosclerosis .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks